Forest Laboratories Announces Appointments to its Executive Team
December 09 2013 - 9:00AM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) today announced
appointments to its executive leadership team. The appointments are
part of Forest’s announced plans to flatten and broaden the
organization as part of Project Rejuvenate.
“Today we are announcing an important step to rejuvenate our
company by creating the first Forest Executive Team with broad
leadership responsibilities, a sharp focus and clear accountability
for driving sustainable growth,” said Brent Saunders, Chief
Executive Officer & President Forest Laboratories.
- Elaine Hochberg is appointed Executive
Vice President, International, Strategic Planning and Government
Affairs.
- Bill Meury is appointed Executive Vice
President, Sales and Marketing.
- Frank Perier, Jr. is appointed
Executive Vice President, Chief Financial Officer.
- Marco Taglietti, MD is appointed
Executive Vice President, Drug Development and Research, and Chief
Medical Officer.
- Bob Bailey is appointed Senior Vice
President, Chief Legal Officer, General Counsel and Corporate
Secretary.
- Alex Kelly is appointed Senior Vice
President, Chief Communications & Investor Relations
Officer.
- Sally Paull is appointed Senior Vice
President, Human Resources.
- Kevin Walsh is appointed Senior Vice
President, Operations.
- Joe Zimmerman is appointed Senior Vice
President, Chief Compliance Officer.
David Solomon, Senior Vice President, Corporate Development and
Strategic Planning will become Senior Advisor to the Chief
Executive Officer responsible for Business Development and Alliance
Management on a transitional basis.
“David played an instrumental role in driving and executing our
company’s successful Next 9 Strategy, which has given us a solid
foundation of future growth drivers,” said Saunders. “During his
transition period, I will draw on David’s experience, expertise and
counsel as we embark on our company’s next chapter.”
As previously announced, the next step in Project Rejuvenate is
for the Forest Executive Team to design and staff their respective
teams in a manner consistent with the principles of flattening and
broadening the organization.
About Forest Laboratories and Its Products
Forest Laboratories (NYSE: FRX) is a leading, fully integrated,
specialty pharmaceutical company largely focused on the United
States market. The Company markets a portfolio of branded drug
products and develops new medicines to treat patients suffering
from diseases principally in five therapeutic areas: central
nervous system, cardiovascular, gastrointestinal, respiratory, and
anti-infective. Our strategy of acquiring product rights for
development and commercialization through licensing, collaborative
partnerships and targeted mergers and acquisitions allows us to
take advantage of attractive late-stage development and commercial
opportunities, thereby managing the risks inherent in drug
development. The Company is headquartered in New York, NY. To learn
more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Frank J. MurdoloVice President, Investor Relations212
224-6714Media.relations@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024